DelveInsight’s, “Merkel Cell Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Merkel Cell Carcinoma pipeline landscape. It covers the Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Merkel Cell Carcinoma Pipeline Outlook Report
Key Takeaways from the Merkel Cell Carcinoma Pipeline Insights Report
- On 24 October 2025, Ariceum Therapeutics Gmbh conducted a study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
- On 17 October 2025, ImmunityBio Inc. announced a study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) in combination with other agents like checkpoint inhibitors and cell therapies across various cancer types and treatment settings. The study includes multiple cohorts based on prior therapies and cancer types, with a focus on assessing overall response rate (ORR), overall survival (OS), and other measures of anti-tumor activity and immune response.
- On 14 October 2025, TuHURA Biosciences Inc. initiated a Phase 2/3 trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via intralesional injection in a single lesion, followed by pembrolizumab.
- DelveInsight’s Merkel Cell Carcinoma pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Merkel Cell Carcinoma treatment.
- The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
- Promising Merkel Cell Carcinoma Therapies such as Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.
Learn how leading Merkel Cell Carcinoma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Merkel Cell Carcinoma Clinical Trials Assessment
Merkel Cell Carcinoma Overview
Merkel cell carcinoma (MCC) is a rare, aggressive form of skin cancer with a high risk for returning (recurring) and spreading (metastasizing), often within two to three years after initial diagnosis. Merkel cells are located deep in the top layer of skin. Merkel cells are connected to nerves, signaling touch sensation as “touch receptors.” MCC tumors often, but not always, appear on sun-exposed areas of the body. The tumors are not nearly as distinctive as other skin cancers and can appear as a pearly pimple-like lump, sometimes skin-colored, red, purple or bluish-red, though they are rarely tender to the touch. Treatments for Merkel cell carcinoma can include: surgery, Radiation therapy, immunotherapy, and chemotherapy.
Merkel Cell Carcinoma Emerging Drugs Profile
- Domatinostat: 4SC
Domatinostat is an orally administered histone deacetylase (HDAC) inhibitor with a unique mode of action that was designed to strengthen the body’s own anti-tumor immune response. Domatinostat “opens” the tumor microenvironment and encourages infiltration of immune cells into the tumor. To advance the development program, 4SC has also signed a drug supply agreement with Merck KGaA for avelumab (anti-PD-L1 antibody) to conduct a Phase II clinical trial of domatinostat in combination with avelumab in advanced-stage Merkel cell carcinoma (MCC) patients progressing on previous anti-PD-(L)1 monotherapy (MERKLIN 2).
- Cavrotolimod: Exicure
Cavrotolimod (AST-008) is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. During the first half of 2019, five clinical trial sites were opened and began dosing patients for the Phase I/II clinical trial. The Phase 1b stage was an open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod (AST-008) injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). Exicure initiated the Phase II stage of the clinical trial with dose-expansion cohorts of intratumoral cavrotolimod in combination with approved checkpoint inhibitors to treat two cohorts of patients with locally advanced or metastatic MCC or CSCC.
The Merkel Cell Carcinoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Merkel Cell Carcinoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Merkel Cell Carcinoma Treatment.
- Merkel Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Merkel Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Merkel Cell Carcinoma market.
Explore the dynamic world of drug development with our latest Merkel Cell Carcinoma Pipeline Insights report! Don’t miss this opportunity to stay informed—download now! @ Merkel Cell Carcinoma Treatment Drugs
Merkel Cell Carcinoma Companies
ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Merkel Cell Carcinoma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Stay updated with the latest Merkel Cell Carcinoma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Merkel Cell Carcinoma Pipeline Report
- Coverage- Global
- Merkel Cell Carcinoma Companies- ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
- Merkel Cell Carcinoma Therapies- Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.
- Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which Merkel Cell Carcinoma Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!” @ Merkel Cell Carcinoma Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Merkel Cell Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Mid Stage Products (Phase II)
- Domatinostat: 4SC
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- XmAb18087: Xencor
- Drug profiles in the detailed report…..
- Preclinical stage products
- SNS-401-NG: Sensei Biotherapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Merkel Cell Carcinoma Key Companies
- Merkel Cell Carcinoma Key Products
- Merkel Cell Carcinoma- Unmet Needs
- Merkel Cell Carcinoma- Market Drivers and Barriers
- Merkel Cell Carcinoma- Future Perspectives and Conclusion
- Merkel Cell Carcinoma Analyst Views
- Merkel Cell Carcinoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/merkel-cell-carcinoma-pipeline-insight